June 6 (Reuters) - Adamis Pharmaceuticals :
* FDA indicated that in order to support approval of product, company must expand its human factors study
* Believes that it can finalize study protocols with FDA and complete additional testing within a "relatively short period of time"
* Believes that it can submit data back to FDA sometime in second half of 2016
* Receives complete response letter from FDA for its epinephrine pre-filled syringe NDA Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)